Paclitaxel News and Research

RSS

Paclitaxel is a drug used to treat breast cancer, ovarian cancer, and AIDS-related Kaposi sarcoma. It is also used together with another drug to treat non-small cell lung cancer. Paclitaxel is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division and may kill cancer cells. It is a type of antimitotic agent. Also called Taxol.

The Paclitaxel compound is extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). Check for active clinical trials or closed clinical trials using this agent.

Gefitinib shows promise in Chinese lung cancer patients

Gefitinib improves progression-free survival, overall response, and health-related quality of life over carboplatin/paclitaxel for first-line advanced non-small-cell lung cancer treatment, a study indicates.

13 Sep 2012

Data from Oncolytics’ REOLYSIN Phase III combination trial on head and neck cancers

Oncolytics Biotech Inc. today provided an update on its Phase III trial of REOLYSIN in combination with carboplatin and paclitaxel for the treatment of head and neck cancers (REO 018).

12 Sep 2012

Bioengineers design nanoparticles that can safely and predictably infiltrate deep into the brain

The brain is a notoriously difficult organ to treat, but Johns Hopkins researchers report they are one step closer to having a drug-delivery system flexible enough to overcome some key challenges posed by brain cancer and perhaps other maladies affecting that organ.

12 Sep 2012

Esperance completes EP 100 and paclitaxel Phase 2 combination trial on advanced ovarian cancer

Esperance Pharmaceuticals today announced the completion of the run-in cohort of its Phase 2, randomized, multi‐center trial of EP‑100 in combination with paclitaxel for patients with advanced ovarian cancer. EP‐100 is a targeted membrane‐disrupting peptide (tMDP) designed to seek and destroy cancer cells that overexpress luteinizing hormone releasing hormone (LHRH) receptors on their surfaces.

29 Aug 2012

Peptide combinations might offer more effective cancer therapy

Two studies suggest that two peptide agents used either together or individually with a low-dose of a standard chemotherapy drug might offer more effective cancer therapy than current standard single-drug treatments.

17 Aug 2012

Drug-eluting stents cleared for diabetes patients

All currently available drug-eluting stents are more effective than bare metal stents (BMS) for patients with diabetes, research suggests.

14 Aug 2012

VEGF inhibitor fails to improve nonsquamous NSCLC overall survival

Adding motesanib to carboplatin–paclitaxel does not boost overall survival in patients with advanced nonsquamous non-small-cell lung cancer, including those with adenocarcinoma, say MONET1 investigators.

8 Aug 2012

Study investigates molecular markers in drug-resistant ovarian cancer

A new study by TCD researchers investigates drug-resistant ovarian cancer cells. The findings which have been recently published in the international publication, PLoS One will increase understanding of molecular markers in drug-resistant ovarian cancer with a view to improving clinical treatment.

27 Jul 2012

Bard completes enrollment in Lutonix DCB clinical trial for peripheral arterial disease

C. R. Bard, Inc. today announced that its Lutonix technology center completed patient enrollment into its global, multicenter LEVANT 2 randomized clinical trial.

26 Jul 2012

VEGF inhibitor fails to improve nonsquamous NSCLC overall survival

24 Jul 2012

Bayer, Onyx and Astellas announce results from Tarceva plus Nexavar Phase 3 trial on HCC

Bayer HealthCare Pharmaceuticals, Onyx Pharmaceuticals, Inc., and Astellas Pharma Inc. today announced that a Phase 3 trial evaluating the efficacy and safety of the addition of Tarceva (erlotinib) tablets to Nexavar (sorafenib) tablets did not improve overall survival for patients with unresectable hepatocellular carcinoma (HCC) vs. Nexavar alone.

23 Jul 2012

Breast cancer drug bevacizumab slows progression but has no overall survival benefit

The cancer drug bevacizumab (Avastin®) offers only a modest benefit in prolonging disease progression in patients with advanced stage breast cancer, according to a systematic review by Cochrane researchers. The researchers assessed the efficacy of bevacizumab in combination with chemotherapy, an established cancer treatment in this indication, and found no overall survival benefit when adding bevacizumab to chemotherapy.

11 Jul 2012

CytRx achieves key milestone in advancing tamibarotene Phase 2b trial for NSCLC

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the recommendation by the Data Safety Monitoring Board (DSMB) to continue with the global Phase 2b clinical trial with tamibarotene in combination with chemotherapeutical agents as a first-line treatment for patients with advanced non-small-cell lung cancer.

26 Jun 2012

Genentech's Perjeta helps people with HER2-positive metastatic breast cancer live longer

Genentech, a member of the Roche Group, announced today that people with HER2-positive metastatic breast cancer (mBC) lived significantly longer (overall survival) when treated with the combination of Perjeta (pertuzumab), Herceptin (trastuzumab) and docetaxel chemotherapy, compared to Herceptin and docetaxel chemotherapy alone in the Phase III CLEOPATRA study.

23 Jun 2012

FORMA, TD2 leverage synergistic capabilities to jointly develop transformative cancer therapies

FORMA Therapeutics and TGen Drug Development (TD2) today announced an agreement to jointly develop transformative cancer therapies, leveraging the synergistic capabilities of both organizations.

19 Jun 2012

Adjuvant chemoradiotherapy boosts esophageal cancer survival

Chemoradiotherapy significantly improves the outcome of patients undergoing surgery for cancer of the esophagus or esophagogastric junction and is well tolerated, suggests research in The New England Journal of Medicine.

7 Jun 2012

Esperance presents results from EP-100 Phase 1 study on solid tumors at ASCO annual meeting

Esperance Pharmaceuticals presented its Phase 1 study of EP-100, a novel targeted membrane‐disrupting peptide (tMDP) in advanced solid tumors at the American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

5 Jun 2012

Results from Celgene’s ABRAXANE plus gemcitabine clinical study on resectable pancreatic cancer

Celgene International Sàrl, a subsidiary of Celgene Corporation today announced results from a study of ABRAXANE(paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in patients with resectable pancreatic cancer.

5 Jun 2012

Duloxetine drug reduces painful chemotherapy-induced peripheral neuropathy in majority of patients

The antidepressant drug duloxetine, known commercially as Cymbalta, helped relieve painful tingling feelings caused by chemotherapy in 59 percent of patients, a new study finds. This is the first clinical trial to find an effective treatment for this pain.

4 Jun 2012

Results from Puma’s PB272 Phase I combination trial on metastatic HER-2 positive breast cancer

Puma Biotechnology, Inc., a development stage biopharmaceutical company, announced that results from an ongoing Phase I clinical trial of its lead drug candidate PB272 (neratinib) given in combination with the anticancer drugs paclitaxel and trastuzumab in patients with metastatic HER-2 positive breast cancer were presented in a poster presentation at the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting.

4 Jun 2012

Paclitaxel News and Research

Further Reading

Gefitinib shows promise in Chinese lung cancer patients

Data from Oncolytics’ REOLYSIN Phase III combination trial on head and neck cancers

Bioengineers design nanoparticles that can safely and predictably infiltrate deep into the brain

Esperance completes EP 100 and paclitaxel Phase 2 combination trial on advanced ovarian cancer

Peptide combinations might offer more effective cancer therapy

Drug-eluting stents cleared for diabetes patients

VEGF inhibitor fails to improve nonsquamous NSCLC overall survival

Study investigates molecular markers in drug-resistant ovarian cancer

Bard completes enrollment in Lutonix DCB clinical trial for peripheral arterial disease

VEGF inhibitor fails to improve nonsquamous NSCLC overall survival

Bayer, Onyx and Astellas announce results from Tarceva plus Nexavar Phase 3 trial on HCC

Breast cancer drug bevacizumab slows progression but has no overall survival benefit

CytRx achieves key milestone in advancing tamibarotene Phase 2b trial for NSCLC

Genentech's Perjeta helps people with HER2-positive metastatic breast cancer live longer

FORMA, TD2 leverage synergistic capabilities to jointly develop transformative cancer therapies

Adjuvant chemoradiotherapy boosts esophageal cancer survival

Esperance presents results from EP-100 Phase 1 study on solid tumors at ASCO annual meeting

Results from Celgene’s ABRAXANE plus gemcitabine clinical study on resectable pancreatic cancer

Duloxetine drug reduces painful chemotherapy-induced peripheral neuropathy in majority of patients

Results from Puma’s PB272 Phase I combination trial on metastatic HER-2 positive breast cancer

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News